ORIC Pharmaceuticals (ORIC) Competitors $5.77 +0.10 (+1.82%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. EVO, IMCR, MESO, ADPT, VERA, DYN, GPCR, ANIP, SPRY, and CALTShould you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Evotec (EVO), Immunocore (IMCR), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. ORIC Pharmaceuticals vs. Evotec Immunocore Mesoblast Adaptive Biotechnologies Vera Therapeutics Dyne Therapeutics Structure Therapeutics ANI Pharmaceuticals ARS Pharmaceuticals Calliditas Therapeutics AB (publ) Evotec (NASDAQ:EVO) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Do analysts prefer EVO or ORIC? Evotec presently has a consensus price target of $5.93, suggesting a potential upside of 45.64%. ORIC Pharmaceuticals has a consensus price target of $19.17, suggesting a potential upside of 219.07%. Given ORIC Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ORIC Pharmaceuticals is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, EVO or ORIC? Evotec has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Is EVO or ORIC more profitable? Evotec's return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A ORIC Pharmaceuticals N/A -44.54%-40.72% Do institutionals and insiders hold more shares of EVO or ORIC? 5.8% of Evotec shares are owned by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 6.8% of ORIC Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer EVO or ORIC? ORIC Pharmaceuticals received 68 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 75.76% of users gave ORIC Pharmaceuticals an outperform vote while only 53.85% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes753.85% Underperform Votes646.15% ORIC PharmaceuticalsOutperform Votes7575.76% Underperform Votes2424.24% Which has better earnings and valuation, EVO or ORIC? Evotec has higher revenue and earnings than ORIC Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$788.22M1.84-$90.82MN/AN/AORIC PharmaceuticalsN/AN/A-$100.70M-$1.87-3.21 Does the media refer more to EVO or ORIC? In the previous week, ORIC Pharmaceuticals had 2 more articles in the media than Evotec. MarketBeat recorded 3 mentions for ORIC Pharmaceuticals and 1 mentions for Evotec. ORIC Pharmaceuticals' average media sentiment score of 1.64 beat Evotec's score of 1.20 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ORIC Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryORIC Pharmaceuticals beats Evotec on 9 of the 14 factors compared between the two stocks. Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$427.59M$6.58B$5.41B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-3.309.2126.7719.96Price / SalesN/A257.57395.44121.37Price / CashN/A65.8538.2534.62Price / Book1.766.576.874.60Net Income-$100.70M$144.25M$3.23B$248.27M7 Day Performance23.60%5.13%5.32%2.28%1 Month Performance23.35%9.67%13.56%16.43%1 Year Performance-32.43%-0.88%17.86%8.15% ORIC Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICORIC Pharmaceuticals4.4986 of 5 stars$5.77+1.8%$19.17+232.0%-37.6%$406.48MN/A-3.1480Gap UpEVOEvotec1.5232 of 5 stars$4.17-3.0%$5.93+42.3%-21.9%$1.48B$788.22M0.004,200Positive NewsIMCRImmunocore2.929 of 5 stars$29.54+4.0%$58.13+96.8%-39.1%$1.48B$310.20M-31.09320Positive NewsMESOMesoblast1.8686 of 5 stars$11.35+3.5%$18.00+58.6%+57.9%$1.45B$5.67M0.0080Gap DownADPTAdaptive Biotechnologies3.5906 of 5 stars$9.51+5.3%$9.83+3.4%+160.7%$1.44B$189.53M-8.72790News CoveragePositive NewsVERAVera Therapeutics3.3901 of 5 stars$22.49+3.6%$63.33+181.6%-48.2%$1.43BN/A-8.6240Positive NewsDYNDyne Therapeutics3.7712 of 5 stars$12.56+10.1%$46.85+273.0%-65.1%$1.43BN/A-3.53100Positive NewsGap DownHigh Trading VolumeGPCRStructure Therapeutics2.1502 of 5 stars$24.62-3.7%$78.00+216.8%-31.1%$1.41BN/A-33.27136ANIPANI Pharmaceuticals4.8404 of 5 stars$62.30-6.0%$80.13+28.6%-1.8%$1.36B$614.38M-113.27600High Trading VolumeSPRYARS Pharmaceuticals2.4614 of 5 stars$13.29-1.1%$31.00+133.3%+55.9%$1.31B$89.15M-26.0690Trending NewsEarnings ReportAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Evotec Competitors Immunocore Competitors Mesoblast Competitors Adaptive Biotechnologies Competitors Vera Therapeutics Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors ANI Pharmaceuticals Competitors ARS Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORIC Stock Free ORIC Stock Alerts